12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avonex interferon beta-1a regulatory update

FDA issued Biogen Idec a Form 483 noting 2 observations of the manufacturing and control operations related to the production of 2 multiple sclerosis drugs - Avonex interferon beta-1a and Tysabri natalizumab - at the biotech's North Carolina manufacturing center. The agency...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >